NCT05652101

Brief Summary

Hereditary hyperekplexia is a rare neuronal disorder, caused by genetic defects leading to dysfunction of glycinergic neurotransmission. The clinical presentation is characterized by stiffness and exaggerated startle responses to unexpected stimuli, that appear shortly after birth. The generalised stiffness can lead to apnea and sudden infant death syndrome. Several genes are known to be associated with hereditary hyperekplexia. The most frequent are Glycine Receptor Alpha 1 (GLRA1), Glycine Receptor Beta (GLRB) and Solute Carrier Family 6 Member 5 (SLC6A5). They encode for the postsynaptic glycine receptor (GLRA1, GLRB) and the presynaptic glycine transport (SLC6A5). Genetic mutations in these genes lead to dysfunction in the glycinergic inhibitory neurotransmission. The neurodevelopment was initially described as normal, or as delayed due to the motor difficulties. Global development delay and intellectual disability are reported as well, in the most recent studies. Nevertheless, the degree of severity of the learning difficulties and the adaptive faculties of the patients is not specified. Similarly, the efficacy of clonazepam in hyperekplexia is well known, but the evolution of dosage over time and the frequency of complete withdrawal have never been studied. The primary endpoint of this study is to describe adaptive skills using a standardized questionnaire, Vineland Adaptive Behavior Scale (VABS2). Secondary endpoints are:

  • Neurodevelopmental course study
  • Description of the evolution of the clinical manifestations over the years
  • Evaluation of the efficacity of the treatment CLONAZEPAM, initially and over time, and evolution of the dosage
  • Comparison of clinical and therapeutical characteristics according to the genotype

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for all trials

Timeline
13mo left

Started Apr 2023

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress74%
Apr 2023Jun 2027

First Submitted

Initial submission to the registry

December 7, 2022

Completed
8 days until next milestone

First Posted

Study publicly available on registry

December 15, 2022

Completed
4 months until next milestone

Study Start

First participant enrolled

April 24, 2023

Completed
4.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2027

Last Updated

August 11, 2025

Status Verified

August 1, 2025

Enrollment Period

4.1 years

First QC Date

December 7, 2022

Last Update Submit

August 8, 2025

Conditions

Keywords

HyperekplexiaNeurodevelopment trajectoryAdaptative skills

Outcome Measures

Primary Outcomes (1)

  • VABS2 total score and specific scores (socialization, communication, daily living and motricity)

    The VABS2 measures adaptative scores in the fields of : * Communication (receptive, expressive, written) * Daily Living Skills (personal, domestic and in community) * Socialisation (interpersonal relationships, play and leisure time, coping skills) * Motor Skills (gross and fine motor) for children under 7 years. The domains are made up of subdomains in which the scores are added to form the domain composite scores. The four domain composite scores then combine to form the adaptive behaviour composite for those individuals aged birth to 6 years 11 months. Three domain composite scores (communication, daily living skills and socialization) combine to form the adaptive behaviour composite for those aged 7 through 90. The results are expressed with standard scores, percentile ranks, adaptive levels and age equivalents.

    maximum 2 months after the inclusion

Study Arms (1)

Patients suffering from hereditary hyperekplexia, above 2 years of age

40 patients suffering from hereditary hyperekplexia will be included. The investigators study patients suffering from hereditary hyperekplexia. The diagnostic is clinical, based on the following symptoms, appearing shortly after birth: stiffness, exaggerating response startles to unexpected stimuli, generalized stiffness after the startles. Children above 2 years old and adults are included, so the neurodevelopment can be evaluated.

Other: collection of medical dataOther: Vineland Adaptive Behaviour Scales (VABS2) questionnaire

Interventions

The data collected concerns: * Sex * Age * Socio-professional category of patients or parents / level of education of the parents * Family history * Neonatal patient data (pregnancy, childbirth) * Clinical data (age of onset of symptoms, evolution of these symptoms over the years, psychomotor development, schooling, learning difficulties, rehabilitation) * Therapeutic data (treatments tried, their dosage and effectiveness, changes in dosage over the years) * Paraclinical examinations (Magnetic Resonance Imaging (MRI), scanner, Electroencephalography (EEG)) * Genetic data if available

Patients suffering from hereditary hyperekplexia, above 2 years of age

This is a standardized semi structured interview that measures adaptative skills in 4 areas, in the fields of communication, socialization, daily living, and motricity (for children under 7 years). It can be used for children and adults. Rating: 2 = yes, usually, 1 = sometimes or partly, 0 = no, never, N = not applicable (when a child is not yet of sufficient age, for example), NS = don't know. The results by domain and by sub-domain are given in raw scores which are then transformed into equivalent ages using a grid provided for this purpose.

Patients suffering from hereditary hyperekplexia, above 2 years of age

Eligibility Criteria

Age2 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Population of patients followed in pediatric neurology or neurology, for hereditary hyperekplexia

You may qualify if:

  • Clinical diagnostic criteria for hyperekplexia (see Thomas et al. BRAIN, 2013):
  • The presence of hypertonia (either hypertonia on examination, axial or segmental, or access of stiffness)
  • Exaggerated reflex startles, to auditory, tactile or visual stimuli
  • The presence of reflex bursts on percussion of the midline
  • Children \>2 years and adults
  • No opposition of one of the two parents (or legal representative) or of the adult patient

You may not qualify if:

  • The presence of a cause secondary to the hyperekplexia (traumatic, autoimmune, etc.)
  • The presence of another cause for a delay in psychomotor development (other neurological pathology, serious head trauma, etc.)
  • Pregnant or breastfeeding women
  • Person deprived of liberty by judicial or administrative decision

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hopital Femme Mère Enfant

Bron, 69500, France

RECRUITING

MeSH Terms

Conditions

Hyperekplexia

Interventions

Surveys and Questionnaires

Condition Hierarchy (Ancestors)

Central Nervous System DiseasesNervous System Diseases

Intervention Hierarchy (Ancestors)

Data CollectionEpidemiologic MethodsInvestigative TechniquesHealth Care Evaluation MechanismsQuality of Health CareHealth Care Quality, Access, and EvaluationPublic HealthEnvironment and Public Health

Central Study Contacts

Laurence LION FRANCOIS, MD,PhD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 7, 2022

First Posted

December 15, 2022

Study Start

April 24, 2023

Primary Completion (Estimated)

June 1, 2027

Study Completion (Estimated)

June 1, 2027

Last Updated

August 11, 2025

Record last verified: 2025-08

Data Sharing

IPD Sharing
Will not share

Locations